Listed

Xtant Medical Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2016

Filed with the SEC on Nov 10, 2016 and accepted by EDGAR at Nov 10, 2016, 16:44 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-07-01 to 2016-09-30$23.1mus-gaap:SalesRevenueNet
Revenue9 months2016-01-01 to 2016-09-30$65.5mus-gaap:SalesRevenueNet
Cost of revenue3 months2016-07-01 to 2016-09-30$7.1mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2016-01-01 to 2016-09-30$20.7mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2016-07-01 to 2016-09-30$16.0mus-gaap:GrossProfit
Gross profit9 months2016-01-01 to 2016-09-30$44.8mus-gaap:GrossProfit
Research and development3 months2016-07-01 to 2016-09-30$928.9kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2016-01-01 to 2016-09-30$2.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-07-01 to 2016-09-30−$1.9mus-gaap:OperatingIncomeLoss
Operating income9 months2016-01-01 to 2016-09-30−$6.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-07-01 to 2016-09-30$3.2mus-gaap:InterestExpense
Interest expense9 months2016-01-01 to 2016-09-30$9.0mus-gaap:InterestExpense
Net income3 months2016-07-01 to 2016-09-30−$4.9mus-gaap:NetIncomeLoss
Net income9 months2016-01-01 to 2016-09-30−$15.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-07-01 to 2016-09-30−$0.40us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2016-01-01 to 2016-09-30−$1.24us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-07-01 to 2016-09-30−$0.40us-gaap:EarningsPerShareBasic
Basic EPS9 months2016-01-01 to 2016-09-30−$1.24us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-07-01 to 2016-09-3012,193,970 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2016-01-01 to 2016-09-3012,064,782 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Capital expenditure9 months2016-01-01 to 2016-09-30$5.6mus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2016-09-30$1.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-09-30$45.8mus-gaap:AssetsCurrent
Total assetsAt period end2016-09-30$142.4mus-gaap:Assets
Current liabilitiesAt period end2016-09-30$28.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-09-30$147.5mus-gaap:Liabilities
Long-term debtAt period end2016-09-30$49.5mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2016-09-30−$5.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-16-133350. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.